| 31st week of 2010 patent applcation highlights part 54 |
| Patent application number | Title | Published |
|---|
| 20100197576 | Polypeptides or fusion proteins thereof inhibiting transmigration of leucocytes or growth and/or metastasis of cancer cells - The present invention provides a polypeptide or its fusion protein derived from a paired immunoglobulin-like receptor α or β (PILRα or PILRβ), one of the transmembrane proteins, which inhibits the transmigration of leukocytes or the growth and/or metastasis of cancer cells. The present invention also provides a polynucleotide encoding the polypeptide or its fusion protein, a vector including the polynucleotide, and a transformant transformed with the vector. The present invention also provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases including the polypeptide or a fusion protein thereof. The present invention also provides a pharmaceutical composition for inhibiting the growth and/or metastasis of cancer cells including the polypeptide or a fusion protein thereof. | 2010-08-05 |
| 20100197577 | NITRIC OXIDE SYNTHASE ACTIVATOR - The object is to find a nitric oxide synthase activator, a method for the administration of the activator, and the amount of the activator to be administered. Disclosed is a nitric oxide synthase activator comprising a midkine family protein or a midkine derivative as an active ingredient. Specifically disclosed is a nitric oxide synthase activator which is intended to be administered through the blood, a coronary artery or a vein and which comprises a midkine family protein or a midkine derivative as an active ingredient. | 2010-08-05 |
| 20100197578 | DEMANNOSYLATED RECOMBINANT FACTOR VIII [[VII]] FOR THE TREATMENT OF PATIENTS WITH HAEMOPHILIA A - There is provided in accordance with the practice of this invention a demannosylated Factor VIII, the immunogenicity of which is substantially decreased or abolished in Human. The modified factor VIII is disclosed together with the modified amino acid sequence, changed by at least one substitution. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory anti-FVIII antibodies. | 2010-08-05 |
| 20100197579 | Corticotropin Releasing Factor 2 Receptor Agonists - Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy. | 2010-08-05 |
| 20100197580 | PARSTATIN PEPTIDES AND USES THEREOF - The invention provides parstatin peptides, particularly a mammalian parstatin peptide including amino acids 1-26 of full length mammalian parstatin, preferably a human parstatin. The invention provides parstatin peptides in appropriate pharmaceutical carriers and formulated for administration. The invention provides for the use of the peptide for example as a medicament or for the preparation of a medicament. The invention provides methods of use for parstatin peptides including for inhibition of angiogenesis, for example for inhibition of ocular angiogenesis, for methods of cardioprotection, and for methods of prevention and treatment of myocardial ischemia-reperfusion injury. | 2010-08-05 |
| 20100197581 | NATIVE GP41 ASSAY - The present invention concerns a method for identifying compounds that decrease the ability of Human Immunodeficiency Virus (HIV) to enter previously uninfected cells. | 2010-08-05 |
| 20100197582 | GROWTH HORMONE FUSION PROTEINS - We disclose growth hormone fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone deficiency that use said proteins. | 2010-08-05 |
| 20100197583 | Glycosaminoglycan-antagonising MCP-1 Mutants and Methods of Using Same - Novel mutants of human monocyte chemoattractant protein 1 (MCP-1) with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type MCP-1, and their use for therapeutic treatment of inflammatory diseases. | 2010-08-05 |
| 20100197584 | USE OF CURCUMIN TO BLOCK BRAIN TUMOR FORMATION IN MICE - The present invention provides compositions and methods of using curcumin or curcumin derivatives or analogs to activate the pro-apoptotic enzymes caspase-3/7 in cancer cells. The present invention also provides formulations of curcumin or derivatives or analogs with increased solubility or improved bioavailability. The formulations may be administered to a subject such that high concentrations of therapeutically effective curcumin compounds resuit in the subject's bloodstream. The invention thus involves the use of curcumin or curcumin derivatives or analogs to diminish cancer cell growth, decrease tumor size, prevent tumor formation, and Curcumin Carrier to reduce or prevent cancer or tumor cell invasion or metastasis into a tissue, e.g., into the nervous System and especially the brain, of a subject. The instant invention may be used prophylactically to prevent tumor formation or metastasis, as a monotherapy to treat existing tumors, after surgery to prevent recurrence of tumors or in conjunction with conventional cancer therapies to improve patient prognosis and reduce side-effects. | 2010-08-05 |
| 20100197585 | USE OF A RGD-PEPTIDE AND/OR PARATHYROID HORMONE (1-34) AS ANTI-HIV AGENT - The present invention is directed to the use of the peptide compound Gly-Arg-Gly-Asp-Asn-Pro as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Gly-Arg-Gly-Asp-Asn-Pro optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 2010-08-05 |
| 20100197586 | USE OF SECRETIN AND OPTIONALLY URODILATIN AS THERAPEUTIC AGENTS - The present invention is directed to the use of the peptide compound His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Arg-Glu-Gly-Ala-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Gly-LeU-Val-NH | 2010-08-05 |
| 20100197587 | USE OF A PEPTIDE AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound His-Ala-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp-Arg-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide His-Ala-Asp-Gly-Ser-Phe-Ser-Asp-Glu-Met-Asn-Thr-Ile-Leu-Asp-Asn-Leu-Ala-Ala-Arg-Asp-Phe-Ile-Asn-Trp-Leu-Ile-Gln-Thr-Lys-Ile-Thr-Asp-Arg-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 2010-08-05 |
| 20100197588 | USE OF A PEPTIDE AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-NH | 2010-08-05 |
| 20100197589 | MODIFIED GROWTH HORMONE POLYPEPTIDES - We describe modified growth hormone fusion proteins and dimers comprising said fusion proteins; nucleic acid molecules encoding said proteins and methods of treatment that use said proteins in the treatment of conditions that result from growth hormone excess. | 2010-08-05 |
| 20100197590 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES - The invention provides compounds of Formula (Ia) | 2010-08-05 |
| 20100197591 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES - The invention provides compounds of the general Formula (I) | 2010-08-05 |
| 20100197592 | VARIANT AXMI-R1 DELTA ENDOTOXIN GENES AND METHODS FOR THEIR USE - Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for pesticidal polypeptides are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, nucleic acid molecules encoding variant AXMI-R1 sequences are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed. | 2010-08-05 |
| 20100197593 | Modulators of the ABC Transporter Family and Methods for their Use - An isolated factor derived from the bacterium | 2010-08-05 |
| 20100197594 | METHODS FOR USING SOY PEPTIDES TO INHIBIT H3 ACETYLATION, REDUCE EXPRESSION OF HMG-COA REDUCTASE AND INCREASE LDL RECEPTOR AND SP1 EXPRESSION IN A MAMMAL - Controlled studies demonstrate that methods using soy related peptides inhibit H3 acetylation, reduce expression of HMG-CoA reductase and increase LDL receptor and Sp1 expression in mammals. The present disclosure is generally directed to using lunasin peptides and/or lunasin peptide derivatives to 1) inhibit H3 acetylation, 2) reduce expression of HMG-CoA reductase, 3) increase LDL receptor expression or 4) increase Sp1 expression in a mammal. In at least one exemplary embodiment of the present disclosure, an effective amount of lunasin peptides or lunasin peptide derivatives and one or more enzyme inhibitors is provided to a mammal to 1) inhibit H3 acetylation, 2) reduce expression of HMG-CoA reductase, 3) increase LDL receptor expression or 4) increase Sp1 expression in a mammal. Additionally, lunasin will protect against, prevent, or reduce: 1) the expression of Matrix metalloproteinase (MMP-1), 2) collagen breakdown, 3) photoaging and 4) the formation of skin wrinkles. | 2010-08-05 |
| 20100197595 | TREATMENT OF MELANOMA WITH ALPHA THYMOSIN PEPTIDES - A method of treating melanoma or a metastasis thereof in a human patient by administering a melanoma-treating effective amount of an alpha thymosin peptide to a human melanoma patient, wherein the human melanoma patient does not have a substantially elevated LDH blood level. | 2010-08-05 |
| 20100197596 | Compositions and methods for diagnosis and treatment of type 2 diabetes - The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics for the treatment or prevention of Diabetes. | 2010-08-05 |
| 20100197597 | Coagulation Factor VII Polypeptides - The present invention relates to novel coagulation Factor VII polypeptides, polynucleotide constructs encoding such polypeptides, as well as vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment. | 2010-08-05 |
| 20100197598 | NOVEL MACROMOLECULE TRANSDUCTION DOMAINS AND METHODS FOR IDENTIFICATION AND USES THEREOF - The present invention discloses novel macromolecule transduction domain (MTD) peptides which facilitate the traverse of a biologically active molecule across the cell membrane. Also disclosed are polynucleotides encoding the MTD peptides, methods of identifying the MTD peptides; methods of genetically engineering a biologically active molecule to have cell permeability by using the MTD peptides, methods of importing a biologically active molecule into a cell by using the MTD peptides, and uses thereof. | 2010-08-05 |
| 20100197599 | USE OF A PEPTIDE AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Met-Ala-Pro-Arg-Gly-Phe-Ser-Cys-Leu-Leu-Leu-Leu-Thr-Ser-Glu-Ile-Asp-Leu-Pro-Val-Lys-Arg-Arg-Ala-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Met-Ala-Pro-Arg-Gly-Phe-Ser-Cys-Leu-Leu-Leu-Leu-Thr-Ser-Glu-Ile-Asp-Leu-Pro-Val-Lys-Arg-Arg-Ala-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 2010-08-05 |
| 20100197600 | USE OF THE PEPTIDE HIS-SER-LEU-GLY-LYS-TRP-LEU-GLY-HIS-PRO-ASP-LYS-PHE ALONE OR IN COMBINATION WITH THE PEPTIDE PRO-GLY-THR-CYS-GLU-ILE-CYS-ALA-TYR-ALA-ALA-CYS-THR-GLY-CYS-OH AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 2010-08-05 |
| 20100197601 | USE OF A FIBRINOGEN RECEPTOR ANTAGONIST AND/OR FOLLICULAR GONADOTROPIN RELEASING PEPTIDE AS A THERAPEUTIC AGENT IN THE TREATMENT OF STREPTOCOCCUS PNEUMONIA INFECTION - The present invention is directed to the use of the peptide compound Ac-Pen-Arg-Gly-Asp-Cys-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurode-generative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Ac-Pen-Arg-Gly-Asp-Cys-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 2010-08-05 |
| 20100197602 | USE OF FOLLICULAR GONADOTROPIN RELEASING PEPTIDE AS A THERAPEUTIC AGENT IN THE TREATMENT OF STREPTOCOCCUS PNEUMONIAE INFECTION - The present invention is directed to the use of the peptide compound Thr-Asp-Thr-Ser-His-His-Asp-Gln-Asp-His-Pro-Thr-Phe-Asn-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Thr-Asp-Thr-Ser-His-His-Asp-Gln-Asp-His-Pro-Thr-Phe-Asn-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 2010-08-05 |
| 20100197603 | USE OF RGDSPASSKP AND OPTIONALLY ANGIOTENSIN II AS THERAPEUTIC AGENTS IN THE TREATMENT OF EG S. PNEUMONIAE INFECTIONS - The present invention is directed to the use of the peptide compound Arg-Gly-Asp-Ser-Pro-Ala-Ser-Ser-Lys-Pro-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Arg-Gly-Asp-Ser-Pro-Ala-Ser-Ser-Lys-Pro-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 2010-08-05 |
| 20100197604 | USE OF PEPTIDE AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 2010-08-05 |
| 20100197605 | THERAPEUTIC USE OF PEPTIDE YGLF AND COMBINATION WITH KVLPVPQ - The present invention is directed to the use of the peptide compound Tyr-Gly-Leu-Phe-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Tyr-Gly-Leu-Phe-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 2010-08-05 |
| 20100197606 | NON-PROTEOLYSABLE OLIGOPEPTIDES THAT INHIBIT GLYCOPROTEIN GP41 OF THE AIDS VIRUS - The invention relates to non-proteolysable oligopeptides that inhibit glycoprotein 41 of the AIDS virus. More specifically, the invention relates to the identification of oligopeptides, particularly hexapeptides, (D), (L) or mixed, preferably D-hexapeptides, which inhibit the binding of a retrovirus to a target cell, thereby providing novel therapies against infection from the human immunodeficiency virus (HIV). The invention also relates to the use of said D-hexapeptides in the form of single components or complex mixtures as prophylactic or therapeutic agents for retroviral infections, especially human immunodeficiency virus type 1 (HIV-1). | 2010-08-05 |
| 20100197607 | MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE - Peptides are provided that comprise less than 24 amino acids. The peptides have an amino acid sequence selected from the group consisting of: (a) an amino acid sequence having from 4 to 6 contiguous amino acids of a reference sequence PEPTIDE 1; (b) an amino acid sequence substantially identical to the sequence defined in (a); and (c) a variant of the amino acid sequence defined in (a). Also provided is a non-myristoylated MANS peptide. Various methods of using the peptides are also provided. | 2010-08-05 |
| 20100197608 | USE OF MELANOTROPHIN-POTENTIATING FACTOR AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Lys-Lys-GIy-Glu-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Lys-Lys-Gly-Glu-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 2010-08-05 |
| 20100197609 | ALKYLAMINO-SUBSTITUTED DICYANOPYRIDINES AND THEIR AMINO ACID ESTER PRODRUGS - The present application relates to novel 6-alkylamino-substituted dicyanopyridines, to their amino acid ester prodrugs, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular disorders. | 2010-08-05 |
| 20100197610 | FRUCTOSE 1, 6 BISPHOSPHATE - A NOVEL ANTICONVULSANT DRUG - The present invention concerns methods and compositions for preventing one or more epileptic seizures in an individual by delivering fructose-1,6-bisphosphate to the individual. In certain cases, an additional therapy for epilepsy is provided to the individual. | 2010-08-05 |
| 20100197611 | ALTERNATIVE AGENT WITH VITAMIN D-LIKE ACTIVITY AND AN IMPROVING AGENT FOR INTESTINAL FUNCTION - The present invention relates to an alternative agent with vitamin D-like activity or an improving agent for age-related depression of intestinal function, comprising a sugar-phosphate ester or a salt thereof, as an active ingredient. | 2010-08-05 |
| 20100197612 | Composition and Methods for the Treatment of Cancer - The present invention discloses anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I | 2010-08-05 |
| 20100197613 | METHODS FOR INHIBITION OF NKT CELLS - Molecules that interact with the NKT cell antigen receptor and its counterpart antigen presenting molecule, but which inhibit the NKT cell immune function, are administered to a patient. Conditions of particular interest include the treatment of systemic lupus erythematosus (SLE), cancer, atherosclerosis, and allergic disease. In some embodiment of the invention, the inhibitory agent is an anergizing glycolipid, for example β-galactosylceramide. Pharmaceutical formulations of such glycolipids are provided, and find use in the treatment of diseases involving undesirable NKT cell activation. | 2010-08-05 |
| 20100197615 | SYNTHESIS OF COMPOUNDS USEFUL AS MODULATORS OF AMYLOID-BETA PRODUCTION - As described herein, the present invention provides methods for preparing compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease. | 2010-08-05 |
| 20100197616 | Proliferation inhibitor of helicobacter pylori including alpha-n-acetyl-glucosaminyl bond-containing monosaccharide derivatives - A method for inhibiting proliferation of | 2010-08-05 |
| 20100197617 | PROCESS FOR THE PREPARATION OF CARALLUMA EXTRACT AND A FORMULATION PREPARED THEREOF - Processes for the preparation of | 2010-08-05 |
| 20100197618 | EXTRACT OF REHMANNIA GLUTINASA LIBOSCH FOR REDUCING BLOOD SUGAR, REDUCING BLOOD FAT, TREATING LEUKEMIA, AND PREPARATION METHOD USES THEREOF - The present invention relates to a | 2010-08-05 |
| 20100197619 | CYCLIN-DEPENDENT PROTEIN KINASES INHIBITORS OF SCUTELLARIA FLAVONOID ORGANIC AMINE DERIVATIVES, SYNTHESIS AND USE THEREOF - The present invention provides a series of cyclin-dependent protein kinases (Cdks) inhibitors, | 2010-08-05 |
| 20100197620 | PESTICIDAL FORMULATIONS - The present invention relates to an active composition for controlling or eradicating Phthiraptera, Siphonaptera and Acarina Pests, typically in domestic animals, comprising a synergistic combination of at least one A83543 compound and at least one macrocyclic lactone. The invention also relates to the use of the active composition in pesticidal formulations, the formulations themselves and to the various applications of those formulations as pesticides, specifically in controlling all species of Phthiraptera, Siphonaptera and Acarina pests, typically in domestic animals. Such applications include the control of such external Phthiraptera, Siphonaptera and Acarina pests in domestic animals including but not limited to sheep, cattle, poultry, pigs, goats, camelids, horses, dogs and cats. | 2010-08-05 |
| 20100197621 | METHODS OF REDUCING THE PROLIFERATION AND VIABILITY OF MICROBIAL AGENTS - The invention relates to formulations of an antimicrobial agent, a lipid, and optionally a surfactant, and uses thereof for reducing the proliferation and viability of microbial agents. | 2010-08-05 |
| 20100197622 | Non-Peptide Macrocyclic Histone Deacetylase (HDAC) Inhibitors and Methods of Making and Using Thereof - Compounds of Formula I or II, and methods of making and using thereof, are described herein. | 2010-08-05 |
| 20100197623 | Anti-Infammatory Macrolide - The compound 3′-N-demethyl-4″-O-(2-diethylaminoethanoyl)-6-O-methyl-9a-aza-9a-homoerythromycin A, having the Formula (I): | 2010-08-05 |
| 20100197624 | ANTHELMINTIC COMBINATION - A method is provided for the treatment of parasitic infestations in mammals, comprising the step of simultaneously or sequentially administering to the mammal effective amounts of (a) 2-desoxoparaherquamide; and (b) abamectin. Also provided is an anthelmintic composition comprising 2-desoxoparaherquamide and abamectin. | 2010-08-05 |
| 20100197625 | SYNTHETIC LIPOPHILIC INOSITOL GLYCANS FOR TREATMENT OF CANCER AND GLUCOSE-METABOLISM DISORDERS - The present intervention related to materials and methods for the synthesis of lipophilic inositol glycan compounds, and salts, solvates and physiological functional derivatives thereof, and their use for the treatment of cancer and glucose-metabolism disorders, such as, for example, diabetes, obesity and metabolic syndrome. | 2010-08-05 |
| 20100197626 | Biomarkers for Depression and Methods Using the Same - The present invention provides various biomarkers of depression. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of depression, methods of determining predisposition to depression, methods of monitoring progression/regression of depression, methods of assessing efficacy of compositions for treating depression, methods of screening compositions for activity in modulating biomarkers of depression, methods of treating depression, as well as other methods based on biomarkers of depression. | 2010-08-05 |
| 20100197627 | PANCREATIC CANCER TREATMENT | 2010-08-05 |
| 20100197628 | METHODS OF TREATING PSYCHIATRIC, SUBSTANCE ABUSE, AND OTHER DISORDERS USING COMBINATIONS CONTAINING OMEGA-3 FATTY ACIDS - The invention provides methods for treating or preventing psychiatric disorders, substance abuse disorders, and other conditions, e.g., cardiovascular disease and cancer, involving administration of a therapeutically-effective amount of a cytosine-containing or cytidine-containing compound, creatine-containing compound, adenosine-containing, adenosine-elevating compound, omega-3 fatty acids, or combinations thereof to a mammal. The invention further provides methods of enhancing neurodevelopment and delaying premature pregnancy by administration of an effective amount of a cytosine-containing or cytidine-containing compound, creatine-containing compound, adenosine-containing, adenosine-elevating compound, omega-3 fatty acids, or combinations thereof to a mammal. | 2010-08-05 |
| 20100197629 | ORAL PHARMACEUTICAL SOLUTIONS CONTAINING TELBIVUDINE - A pharmaceutical solution suitable for oral administration comprising β-L-thymidine/2′-deoxy-L-thymidine (telbivudine), a pharmaceutically suitable solvent system, one or more taste-enhancing/masking agents, a preservative system, and a buffer system suitable to allow both drug stability and preservation. | 2010-08-05 |
| 20100197630 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES - Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are potent CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In formula I, A-B is an arylamide moiety. | 2010-08-05 |
| 20100197631 | HYALURONIC ACID DERIVATIVES CONTAINING GROUPS ABLE TO RELEASE NO - Disclosed are hyaluronic acid derivatives functionalised with S-nitrosothiol groups of the general formula: wherein HA indicates hyaluronic acid and G indicates a suitable spacer. | 2010-08-05 |
| 20100197632 | ANTI-INFLAMMATORY DERMATOLOGICAL COMPOSITION COMPRISING CORTICOSTEROIDS AND HYALURONATE FRAGMENTS, AND USES THEREOF - Anti-inflammatory dermatological composition for topical administration, characterized in that it comprises 0.005% to 0.1%, preferably 0.01% to 0.05% by weight of a corticosteroid and 0.1% to 1%, preferably 0.5% to 1% by weight of hyaluronate fragments with an average molecular weight of between 20 and 500 kDa, preferably between 20 and 375 kDa, more preferentially between 20 and 150 kDa. | 2010-08-05 |
| 20100197633 | N-Alkyl-Heterocyclyl Carboxamide Derivatives - A compound of general formula (I): | 2010-08-05 |
| 20100197634 | INHIBITORS OF JANUS KINASES - The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer. | 2010-08-05 |
| 20100197635 | TREATMENT OF TARDIVE DYSKINESIA WITH PYRIDOXAL 5'-PHOSPHATE - This invention relates to treatment of Tardive Dyskinesia through the administration of pyridoxal 5′-phosphate. The treatment may be an oral administration of 100-4000 mg/day, for example, 100-750 mg/day or about 250 mg/day. Also provided is the use of pyridoxal 5′-phosphate for the preparation of a medicament for the treatment of tardive dyskinesia, kits comprising pyridoxal 5′-phosphate for the treatment of tardive dyskinesia, and combination drugs for the treatment of tardive dyskinesia. | 2010-08-05 |
| 20100197636 | INJECTABLE CALCIUM-PHOSPHATE CEMENT RELEASING A BONE RESORPTION INHIBITOR - The present invention relates to a macroporous, resorbable and injectable apatitic calcium-phosphate cement with a high compressive strength useful as bone cement and releasing a bone resorption inhibitor, preparation method and uses thereof. | 2010-08-05 |
| 20100197637 | Method of Treatment Using Bisphosphonic Acid - The present invention refers to a pharmaceutical composition of a bisphosphonic acid or salt thereof, and an excipient thereof, and a method of treating disorder characterized by pathologically increased bone resorption comprising orally administering at least 150% of the expected efficious daily dose of a bisphosphonic acid or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients thereof and administering the dose at a period of one two or three consecutive days per month. | 2010-08-05 |
| 20100197638 | Skin Beautifying Agent - The present invention aims to provide a skin-beautifying agent, food, beverage, or feed for skin-beautification which has cosmetic effects such as moisturizing and beautifying the skin as well as preventing skin roughness and wrinkles by oral intake. The present invention further aims to provide a skin-beautifying agent containing a milk-derived phospholipid as an effective ingredient, and to provide food, beverage, or feed for skin-beautification containing the skin-beautifying agent. The milk-derived phospholipid is preferably a composition prepared from milk or milk material containing 40 to 70% by weight of lipid in a total solid content and containing 30% or more by weight of milk-derived phospholipid. | 2010-08-05 |
| 20100197639 | Methods and Devices for Analysis of X-Ray Images - The present invention relates to methods and devices for analyzing x-ray images. In particular, devices, methods and algorithms are provided that allow for the accurate and reliable evaluation of bone structure from x-ray images. | 2010-08-05 |
| 20100197640 | NOVEL SULFAMOYL-PHENYL-UREIDO COMPOUNDS AND THEIR USE AS MEDICAMENT - The present invention relates to novel sulfamoyl-phenyl-ureido compounds having the formula (I) or a physiologically acceptable salt or derivative thereof which are suitable for the therapy of infections caused by protozoa and in particular uncomplicated or severe malaria caused by plasmodia. | 2010-08-05 |
| 20100197641 | FORMULATION FOR LIPOPHILIC AGENTS - The invention relates to pharmaceutical formulations of lipophilic therapeutic agents in which such agents are solubilized in largely aqueous vehicles, and processes for preparing and using the same. | 2010-08-05 |
| 20100197642 | SLOW RELEASE MISOPROSTOL FOR OBSTETRIC AND/OR GYNAECOLOGICAL APPLICATIONS - Described are medical applications of Misoprostol defined by a particular combination of sustained release or slow release dosage form and oral administration route for obstetric and/or gynaecological conditions and treatments. Further described are combination medications of Mifepristone with the aforementioned Misoprostol dosage form and administration. | 2010-08-05 |
| 20100197643 | PHYTOCHEMICAL-RICH OILS AND METHODS RELATED THERETO - The invention relates to methods used in extracting oil from plants, plant fruits, and/or nuts, preferably fruits from plants of the family Arecaceae, or Palmae, even more preferably acai fruit. In some embodiments, the invention relates to methods of extracting the oil using an extraction solution comprising a volatile alcohol and volatile ketone. In other embodiments, the invention relates to oil from acai fruit and acai fruit by-products that contain enriched concentrations of phytochemicals. | 2010-08-05 |
| 20100197644 | Chemical Compounds 572 - Compounds of formula (I): | 2010-08-05 |
| 20100197645 | Thioamide Derivatives as Progesterone Receptor Modulators - Thioamide compounds, and specifically, thioamide pyrrole compounds, and preparation thereof are provided. These thioamide compounds can be used as progesterone receptor modulators, in contraception, and in the treatment of progesterone-related maladies. | 2010-08-05 |
| 20100197646 | SOLVENT-BASED STERILISATION OF PHARMACEUTICALS - A sterile composition of a pharmaceutical compound is prepared by combining solvent with a non-sterile pharmaceutical compound to form a solution and filtering to yield a sterile pharmaceutical compound, optionally removing all or part of the solvent, and under sterile conditions combining the compound with a pharmaceutically acceptable carrier. | 2010-08-05 |
| 20100197647 | COMPOUNDS THAT INHIBIT OESTRONE SULPHATASE; COMPOSITIONS THEREOF; AND METHODS EMPLOYING THE SAME - Disclosed and claimed are compounds suitable for use as an inhibitor of oestrone sulphatase in a subject in need thereof, as well as compositions containing such compounds and methods for using such compounds. Such compounds can be a sulphamate compound that has the Formula (X) and wherein X is a sulphamate group, and Y is CH | 2010-08-05 |
| 20100197648 | Treatment of irritable bowel syndrome and related bowel disease - The present invention discloses a method of treating an individual having irritable bowel syndrome or a related disorder, comprising the step of administering to said individual a pharmacologically effective dose of a luminally active anti-inflammatory or immunosuppressive compound with minimal or no systemic side effects. Further provided is a method of inhibiting the onset of symptoms of irritable bowel syndrome or a related disorder in an individual in need of such treatment, comprising the step of administering to the individual a prophylactically effective dose of a luminally active anti-inflammatory or immunosuppressive compound with minimal or no systemic side effects. | 2010-08-05 |
| 20100197649 | Compositions and Methods for Diagnosing and Treating Community-Acquired Methicillin-Resistant Staphylococcus Aureus - The present invention includes compositions and methods for diagnosing and treating CA-MRSA infections in patients. The methods are based on the finding that combining cefoxitin and a synthetic penicillin in a treatment regimen results in a synergistic effect of the two drugs, an effect that is related to PBP4 activity in CA-MRSA isolates. Also provided is a CA-MRSA-specific biomarker which can be used to detect the presence of a CA-MRSA infection in a patient. | 2010-08-05 |
| 20100197650 | COMPOSITIONS AND METHODS OF TREATMENT COMPRISING CEFTAROLINE - The present invention provides compositions comprising ceftaroline or a pharmaceutically acceptable salt, solvate or a prodrug thereof alone or in combination with an antibacterial agent. The present invention provides methods of treating bacterial infection, which include administering an effective amount of ceftaroline or a pharmaceutically acceptable salt, solvate or a prodrug thereof alone or in combination with an antibacterial agent. | 2010-08-05 |
| 20100197651 | Pyridazinone compounds - The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. | 2010-08-05 |
| 20100197652 | PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS - The present invention is directed to pyridyl carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved. | 2010-08-05 |
| 20100197653 | NOVEL CARBAPENEM DERIVATIVES - The present invention relates to novel carbapenem derivatives and belongs to pharmaceutical field. Specifically, the present invention relates to the compounds as represented by formulae (1) and (2), pharmaceutically acceptable salts, hydrolysable esters, isomers and intermediates thereof, wherein R | 2010-08-05 |
| 20100197654 | TRIAZINE KINASE INHIBITORS - The invention provides compounds of formula I | 2010-08-05 |
| 20100197655 | SULFONAMIDE DERIVATIVES - The present invention relates to compounds of the formula | 2010-08-05 |
| 20100197656 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES - Dihydrothienopyrimidines of formula 1 | 2010-08-05 |
| 20100197657 | 2-ARYL OR HETEROARYL INDOLE DERIVATIVES - The present invention provides 2-aryl or heteroaryl indole derivatives which are ASIC channel modulators, maceutical compositions containing such compounds, and methods of using them as therapeutic agents. | 2010-08-05 |
| 20100197658 | PHARMACEUTICAL USE OF FUSED 1,2,4-TRIAZOLES - Methods of using fused 1,2,4-triazoles for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable, including type 2 diabetes and metabolic syndrome. | 2010-08-05 |
| 20100197659 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS - The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I. | 2010-08-05 |
| 20100197660 | AZEPINE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS - Compounds of formula (I), pharmaceutical compositions comprising them, and methods for their use are described. | 2010-08-05 |
| 20100197661 | Method of Treating Neurological Diseases and Disorders - The present invention provides methods for treating neurological diseases and disorders. Compounds that replace or enhance the function of SMN or alleviate or reduce a phenotype of cells with low SMN protein levels are provided. Screening methods and kits for identifying such compounds also are provided. | 2010-08-05 |
| 20100197662 | HETEROCYCLIC COMPOUND HAVING TYPE I 11 BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY - Disclosed is a compound useful as a type I 11βhydroxysteroid dehydrogenase inhibitor. A compound represented by the formula: | 2010-08-05 |
| 20100197663 | METHOD AND COMPOSITIONS FOR TREATMENT OF PAINFUL DISORDERS - Chronic pain is treated with a combination of a standard dose of a non-narcotic analgesic and a low dose of a tricyclic antidepressant compound. The invention is effective in the treatment of chronic pain associate with neuropathic or fibromuscular disorders, where such pain has been unresponsive to non-narcotic analgesics alone. | 2010-08-05 |
| 20100197664 | NOVEL B1-ANTAGONISTS - Disclosed are compounds of the formula I | 2010-08-05 |
| 20100197665 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER - Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a dysregulated protein kinase activity, like cancer formula (I). | 2010-08-05 |
| 20100197666 | (THIO) -CARBAMOYL-CYCLOHEXANE DERIVATIVES AND METHOD FOR TREATING SCHIZOPHRENIA - The present invention relates to use of (thio)-carbamoyl-cyclohexane derivatives, particularly trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of schizophrenia. Furthermore, the present invention relates to the treatment of schizophrenia through the administration of (thio)-carbamoyl cyclohexane derivatives, particularly trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine and pharmaceutically acceptable salts thereof. | 2010-08-05 |
| 20100197667 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS - The invention provides compounds of formula I: | 2010-08-05 |
| 20100197668 | 1,2,3,4-TETRAHYDROPYRROLO[1,2-A]PYRAZINE-6-CARBOXAMIDE AND 2,3,4,5-TETRAHYDROPYRROLO[1,2-a][1,4]-DIAZEPINE-7-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF - The present invention relates to derivatives of 1,2,3,4-tetrahydropyrrolo-[1,2-a]pyrazine-6-carboxamides and of 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]diazepine-7-carboxamides, to the preparation thereof and to the therapeutic use thereof. | 2010-08-05 |
| 20100197670 | AMIDINE, THIOUREA AND GUANIDINE DERIVATIVES OF 2-AMINOBENZOTHIAZOLES AND AMINOBENZOTHIAZINES FOR THEIR USE AS PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE PATHOLOGIES - Amidine, thiourea and guanidine derivatives of appropriately substituted 2-aminobenzothiazoles, 2-amino-3,1-4H-benzothiazines and 3-amino-1,4-3H-benzothiazines, as understood from formula (I), the related pharmaceutically acceptable salts and solvates thereof: | 2010-08-05 |
| 20100197671 | PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF - The present invention relates to phenyl amino pyrimidine compounds which are inhibitors of protein kinases including JAK kinases. In particular the compounds are selective for JAK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases. | 2010-08-05 |
| 20100197672 | PYRROLE COMPOUNDS AS INHIBITORS OF MYCOBACTERIA, SYNTHESIS THEREOF AND INTERMEDIATES THERETO - The present invention relates to a compound having the general formula (3): synthesis, intermediates and uses thereof. | 2010-08-05 |
| 20100197673 | INDOLE AND INDAZOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS - The present invention relates to indole or indazole compounds, pharmaceutically acceptable salts or isomers thereof which are useful for the prevention or treatment of cellular necrosis and necrosis-associated diseases. The present invention also relates to a method and a composition for the prevention or treatment of cellular necrosis and necrosis-associated diseases, comprising said indole or indazole compounds as an active ingredient. | 2010-08-05 |
| 20100197674 | OXOPYRAZINE DERIVATIVE AND HERBICIDE - The present invention is to provide an oxopyrazine derivative having an excellent herbicidal activity and besides exhibiting high safety for useful crops and the like, or a salt thereof, and a herbicide containing the same. | 2010-08-05 |
| 20100197675 | CYCLIC UREA AND CARBAMATE INHIBITORS OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE 1 - This invention relates to novel compounds of the Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell. | 2010-08-05 |
| 20100197676 | 5-Substituted-2-Phenylamino Benzamides as Mek Inhibitors - An objective of the present invention is to provide compounds that exhibit strong MEK-inhibiting activity and are stable in vivo and soluble in water, which can be used as preventive or therapeutic agents for proliferative diseases. | 2010-08-05 |
| 20100197677 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES - The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, | 2010-08-05 |
